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Abstract
Background & Aim
Whether inosine triphosphatase (ITPA) gene polymorphisms predict anemia during inter-
feron-free therapy in chronic hepatitis C virus (HCV)-infected patients is unknown. We
examined the relationship between two ITPA polymorphisms, anemia, and sustained viro-
logical response 12 weeks post-treatment (SVR12) in patients receiving the NS3/4A prote-
ase inhibitor faldaprevir, the non-nucleoside polymerase inhibitor deleobuvir, and ribavirin.
Methods
HCV genotype 1-infected, treatment-naïve patients (N = 362) were randomized and treated
in one of five treatment arms with faldaprevir and deleobuvir with or without ribavirin. Two
ITPA polymorphisms (rs1127354 and rs6051702) were genotyped and defined as ITPA-
deficient (rs1127354 AA or AC; rs6051702 CC or CA) or ITPA-non-deficient (rs1127354
CC; rs6051702 AA) according to their association with ITPA deficiency. Baseline and on-
treatment variables associated with anemia and SVR12 were identified using logistic
regression.
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Results
In the pooled ribavirin-containing arms, 10.1% (32/316) of patients experienced on-treat-
ment hemoglobin <10 g/dL, and 32.6% (103/316) experienced on-treatment hemoglobin
<10 g/dL or a change from baseline3.5 g/dL. Of the latter group, 99% (102/103) had the
ITPA-non-deficient rs1127354 genotype. Other variables associated with on-treatment
hemoglobin <10 g/dL or a decrease3.5 g/dL were age, baseline hemoglobin, rs6051702
genotype, and plasma ribavirin concentration. In a multivariate analysis, high plasma ribavi-
rin concentration, low baseline hemoglobin, HCV genotype 1b, and IL28B genotype CC
were associated with higher SVR12.
Conclusions
The ITPA rs1127354 CC and rs6051702 AA genotypes may predict ribavirin-induced ane-
mia during treatment with interferon-free, ribavirin-containing regimens. With this inter-
feron-free regimen, SVR was associated with ribavirin levels, but not with anemia or ITPA
genotypes.
Trial Registration
ClinicalTrials.gov: NCT01132313
Introduction
Ribavirin is an important component of interferon-containing regimens for the treatment of
chronic hepatitis C virus (HCV) infection, and is also included in many interferon-free regi-
mens currently in development [1–5]. Among patients receiving ribavirin with peginterferon,
anemia is common, often resulting in ribavirin dose reduction or discontinuation [1–3, 6].
Anemia is likely due to a ribavirin-associated, dose-dependent hemolytic anemia which may be
worsened by the myelosuppressive action of peginterferon. Ribavirin-induced anemia has also
been observed in trials of interferon-free, ribavirin-containing regimens in development for
chronic HCV [4, 5, 7, 8]. For HCV genotype 2 infection, sofosbuvir plus ribavirin is recom-
mended [9]. For HCV genotype 4 infection, sofosbuvir plus ribavirin for 24 weeks has been
proposed [10]. The interferon-free paritaprevir (previously ABT-450)-based regimen also con-
tains ribavirin [5]. Predicting anemia during treatment with ribavirin-containing, interferon-
free regimens is essential for optimal patient management, particularly when treating special
populations such as patients with high cardiovascular risk.
Genetic variation in the inosine triphosphatase (ITPA) gene on chromosome 20 is associ-
ated with the development of anemia during peginterferon and ribavirin therapy [11–13]. Sin-
gle-nucleotide polymorphisms (SNPs) at or near this locus have been found to be associated
with ribavirin-induced anemia. The mechanism underlying this association is not well under-
stood, but one hypothesis is that reduced ITPA activity in erythrocytes leads to higher levels of
inosine triphosphate (ITP). ITP, in turn, can substitute for guanosine triphosphate, allowing
the synthesis of adenosine triphosphate (ATP), and the resulting protection against ATP
depletion may prevent ribavirin-induced anemia [14, 15]. For the clinician, determining the
presence of ITPA SNPs may help predict the development of anemia during chronic HCV
treatment. There are currently no reports in the peer-reviewed literature on the effects of ITPA
SNPs on ribavirin-induced anemia during interferon-free therapy.
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The SOUND-C2 study was a phase 2b, randomized, open-label study of the HCV NS3/4A
protease inhibitor faldaprevir and the non-nucleoside NS5B polymerase inhibitor deleobuvir
with or without ribavirin in treatment-naïve, chronic HCV genotype 1-infected patients [16].
Efficacy results showed that rates of sustained virological response at 12 weeks post-treatment
(SVR12) were significantly higher in the ribavirin-containing arms (52–69%) than in the riba-
virin-free arm (39%; p = 0.003) [16]. Rates were higher among genotype 1b-infected patients
(up to 85% and 57% in the ribavirin-containing and ribavirin-free arms, respectively), and
among patients who completed therapy (i.e., excluding those who discontinued early for rea-
sons unrelated to efficacy; 66–72% and 46% in the ribavirin-containing and ribavirin-free
arms, respectively) [16], (BI data on file). We analysed hemoglobin reductions in patients
treated with faldaprevir, deleobuvir, and ribavirin in the SOUND-C2 study. This report
describes the incidence of anemia during SOUND-C2 and any baseline factors associated
with anemia. We specifically analysed two SNPs, one within (rs1127354) and one adjacent to
(rs6051702) the ITPA gene.
Since the completion of this analysis, the development of faldaprevir and deleobuvir has
been terminated. However, since ribavirin is an important component of many interferon-free
regimens, and the effects of ITPA polymorphisms on interferon-free, ribavirin-containing regi-
mens are unknown, this analysis provides information that may be relevant to other HCV
treatment regimens.
Materials and Methods
Study design and patient population
In the SOUND-C2 study, 362 HCV genotype 1-infected, treatment-naïve patients were ran-
domized and treated in one of five treatment groups: faldaprevir 120 mg once daily and deleo-
buvir 600 mg three times daily plus ribavirin for 16 weeks (TID16W), 28 weeks (TID28W), or
40 weeks (TID40W); faldaprevir 120 mg once daily and deleobuvir 600 mg twice daily plus
ribavirin for 28 weeks (BID28W); or faldaprevir 120 mg once daily and deleobuvir 600 mg
three times daily, without ribavirin, for 28 weeks (TID28W-NR) [16]. Randomization was
stratified by viral subtype (1a or 1b) and by IL28B (rs12979860) genotype (CC or non-CC).
The primary efficacy end point was SVR12 (undetectable HCV RNA at 12 weeks post-treat-
ment). Ribavirin was dosed twice daily at 1000–1200 mg per day according to body weight
(1000 mg for body weight<75 kg; 1200 mg for body weight75 kg). Ribavirin dose reductions
and erythropoietin use were permitted for the management of anemia. Hemoglobin levels were
measured at baseline, day 4, weeks 1, 2, 4, 6, and 8, then every 4 weeks through the end of
treatment.
The study was approved by the institutional review board/independent ethics committee of
each participating site, and was carried out in compliance with the ethical guidelines of the
Declaration of Helsinki and in accordance with the International Conference on Harmonisa-
tion Guidelines for Good Clinical Practice. All patients provided written informed consent
prior to enrolment, and gave separate consent for genetic testing.
Statistical analysis
Anemia was defined as on-treatment hemoglobin<10 g/dL or a decrease from baseline of3.5
g/dL, consistent with Division of AIDS Table for Grading the Severity of Adult and Pediatric
Adverse Events grade2 changes. Categorical variables are reported as frequencies and per-
centages. Continuous data are expressed as means. Using pooled data from the ribavirin-con-
taining arms, baseline and on-treatment variables significantly (determined by p<0.05)
associated with the development of anemia were identified using logistic regression. The analysis
ITPAGenotypes and Anemia with Faldaprevir
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was restricted to patients with the ITPA-non-deficient rs1127354 CC genotype because nearly
all patients with anemia had the ITPA-non-deficient CC genotype at this locus, and only one
patient with an ITPA-deficient rs1127354 genotype had anemia, consistent with what has been
reported in the literature [11, 12]. Variables identified as significant in the univariate analysis
were evaluated using multivariate logistic regression. Using the data set of patients who com-
pleted therapy (excluding those who discontinued for reasons unrelated to efficacy), univariate
and multivariate logistic regression analyses were used to identify baseline and on-treatment
factors associated with SVR12.
ITPA genotyping
Genomic DNA was extracted using magnetic bead technology. DNA concentration and quality
was determined by absorbance measurements at 260 nm and 280 nm using a μQuant™micro-
plate spectrophotometer. ITPA genotyping (rs1127354 and rs6051702) was performed by high
resolution melting curve analysis using a LightCycler1 480 real-time PCR system. ITPA geno-
types were defined as ITPA-deficient (rs1127354 AA or AC and rs6051702 CC or CA) or
ITPA-non-deficient (rs1127354 CC and rs6051702 AA) based on their association with ITPA
deficiency and hemolytic anemia in previous studies [11, 12]. The distribution of genotypes
was tested by Hardy-Weinberg equilibrium.
Results
Patient characteristics and incidence of anemia
Baseline demographic and disease characteristics are shown in Table 1. The majority of
patients were white and approximately half were male. The mean age of patients (45.3–48.9
years) and baseline hemoglobin levels (14.8–15.1 g/dL) were similar across the arms. Nearly
one-quarter of patients (23%; 85/362) had advanced fibrosis (F3 or F4). The highest rates of cir-
rhosis were in the TID16W (11.1%) and BID28W (11.5%) arms.
Anemia was not detected among patients in the ribavirin-free arm [16]; therefore, this anal-
ysis focuses principally on patients in the ribavirin-containing arms. Of 316 patients who
received ribavirin, 103 (32.6%) had on-treatment hemoglobin<10 g/dL (32 patients, 10.1%) or
a change from baseline of3.5 g/dL. The mean reduction in hemoglobin at the end of treat-
ment in the pooled ribavirin-containing arms was approximately 2.5 g/dL. Fig 1 shows mean
hemoglobin levels by treatment group over time. Among patients in the ribavirin-containing
arms with an on-treatment hemoglobin of<10 g/dL or a change from baseline of3.5 g/dL,
the median time to the first occurrence of such an event was 42 days. Fig 2 shows the probabil-
ity of anemia (hemoglobin<10 g/dL or decrease of3.5 g/dL) over time for the pooled ribavi-
rin-containing arms.
Reductions in hemoglobin levels appear not to have had an impact on SVR12. As shown in
Table 2, 65% (67/103) of patients who had hemoglobin<10 g/dL or a decrease from baseline
3.5 g/dL achieved SVR12, compared with 57% (122/213) of patients who did not experience
anemia.
ITPA SNPs and anemia events
ITPA data were available for 360 of the 362 patients in the study. Genotype frequency for each
variant was in agreement with Hardy–Weinberg equilibrium in the tested population. The vast
majority of patients (81–91%) across all arms had the ITPA-non-deficient rs1127354 CC geno-
type, while 58–76% of patients had the ITPA-non-deficient rs6051702 AA genotype (Table 3).
Almost all patients with the rs6051702 AA genotype had the ITPA-non-deficient genotype at
ITPAGenotypes and Anemia with Faldaprevir
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Table 1. Baseline demographics and disease characteristics.
Parameter TID16W (N = 81) TID28W (N = 80) TID40W (N = 77) BID28W (N = 78) TID28W-NR (N = 46)
Male, n (%) 45 (55.6) 41 (51.3) 36 (46.8) 41 (52.6) 24 (52.2)
Race, n (%)
White 79 (97.5) 78 (97.5) 76 (98.7) 77 (98.7) 46 (100.0)
Black/African American 2 (2.5) 1 (1.3) 0 1 (1.3) 0
Asian 0 1 (1.3) 0 0 0
Other 0 0 1 (1.3) 0 0
Age, mean (SD), years 48.6 (11.3) 47.3 (11.2) 48.9 (10.7) 47.9 (11.1) 45.3 (13.0)
Body mass index, mean kg/m2 25.3 25.5 24.8 25.0 25.5
Cirrhosis, n (%) 9 (11.1) 7 (8.8) 5 (6.5) 9 (11.5) 3 (6.5)
IL28B genotype, n (%)
CC 21 (25.9) 21 (26.3) 19 (24.7) 19 (24.4) 12 (26.1)
Non-CC 60 (74.1) 58 (72.5) 58 (75.3) 59 (75.6) 33 (71.7)
Missing 0 1 (1.3) 0 0 1 (2.2)
Genotype 1 subtype, n (%)
1a 34 (42.0) 32 (40.0) 34 (44.2) 30 (38.5) 18 (39.1)
1b 47 (58.0) 48 (60.0) 43 (55.8) 48 (61.5) 28 (60.9)
HCV RNA 800,000 IU/mL, n (%) 70 (86.4) 66 (82.5) 67 (87.0) 66 (84.6) 36 (78.3)
Baseline hemoglobin, mean (SD), g/dL 15.1 (1.0) 14.8 (1.0) 14.9 (1.0) 14.8 (1.3) 15.0 (1.0)
Fibrosis stage,a n (%)
F2 63 (77.8) 58 (72.5) 62 (80.5) 57 (73.1) 35 (76.1)
F3–F4 17 (21.0) 21 (26.3) 15 (19.5) 21 (26.9) 11 (23.9)
Missing 1 (1.2) 1 (1.3) 0 0 0
aFibrosis stage was determined by either METAVIR score or ﬁbroscan result; if a METAVIR score was not available, then a ﬁbroscan result was used
(ﬁbroscan <9.5 = F2 and ﬁbroscan 9.5 = F3). TID16W/TID28W/TID40W, faldaprevir 120 mg once daily and deleobuvir 600 mg three times daily plus
ribavirin for 16, 28, and 40 weeks, respectively; BID28W, faldaprevir 120 mg once daily and deleobuvir 600 mg twice daily plus ribavirin for 28 weeks;
TID28W-NR, faldaprevir 120 mg once daily and deleobuvir 600 mg three times daily, without ribavirin, for 28 weeks.
doi:10.1371/journal.pone.0144004.t001
Fig 1. Hemoglobin levels over time.Mean hemoglobin by treatment group over time is shown. The mean
reduction at the end of treatment for the pooled ribavirin-containing arms was approximately 2.5 g/dL.
TID16W/TID28W/TID40W, faldaprevir 120 mg once daily, deleobuvir 600 mg three times daily, and ribavirin
for 16, 28, and 40 weeks, respectively; BID28W, faldaprevir 120 mg once daily, deleobuvir 600 mg twice
daily, and ribavirin for 28 weeks; TID28W-NR, faldaprevir 120 mg once daily and deleobuvir 600 mg three
times daily without ribavirin for 28 weeks.
doi:10.1371/journal.pone.0144004.g001
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both positions (rs6051702 and rs1127354). Patients with the rs1127354 CC genotype were
observed to have a greater reduction in mean hemoglobin over time than those with ITPA-
deficient genotypes (AA/AC) at this position (Fig 3). The difference between mean hemoglobin
levels over time was less pronounced between those with ITPA-deficient and–non-deficient
rs6051702 genotypes (Fig 3).
Predictors of anemia and virological response
Only one of the 103 patients with anemia (hemoglobin<10 g/dL or decreased from baseline
by3.5 g/dL) had the ITPA-deficient AA or AC genotype at rs1127354. Ninety-nine percent
(102/103) had the ITPA-non-deficient rs1127354 CC genotype, while 77% (79/103) had the
ITPA-non-deficient rs6051702 AA genotype (Table 4). Therefore, the probability of experienc-
ing an anemia event (hemoglobin<10 g/dL or decreased by3.5 g/dL) based on selected base-
line and on-treatment factors was explored among patients with the rs1127354 CC genotype
only. Using logistic regression analysis on pooled data from the ribavirin-containing treatment
arms, the association of anemia with the following factors was explored: gender, age (<60 years
vs60 years), weight (<75 kg vs75 kg), body mass index (<25 kg/m2 vs25 kg/m2), fibro-
sis stage (F0–F2 vs F3–F4), presence of cirrhosis (yes/no), baseline hemoglobin (<15 g/dL vs
15 g/dL), rs6051702 genotype (ITPA-deficient (CC/CA) vs ITPA-non-deficient (AA])), ini-
tial ribavirin dose, and faldaprevir, deleobuvir, and ribavirin trough concentrations through
Fig 2. Probability of anemia over time. Among patients in the pooled ribavirin-containing arms with anemia,
the median time to the first occurrence of anemia was 42 days.
doi:10.1371/journal.pone.0144004.g002
Table 2. Rates of SVR12 by incidence of anemia in pooled ribavirin-containing arms.
n/N (%) TID16W TID28W TID40W BID28W Total
All patients, Hb 10 g/dL and no reduction 3.5 g/dL 33/57 (58) 32/55 (58) 22/49 (45) 35/52 (67) 122/213 (57)
Genotype 1a 10/26 (38) 10/24 (42) 10/24 (42) 8/20 (40) 38/94 (40)
Genotype 1b 23/31 (74) 22/31 (71) 12/25 (48) 27/32 (84) 84/119 (71)
All patients, Hb <10 g/dL or reduction 3.5 g/dL 15/24 (63) 15/25 (60) 18/28 (64) 19/26 (73) 67/103 (65)
Genotype 1a 3/8 (38) 4/8 (50) 6/10 (60) 5/10 (50) 18/36 (50)
Genotype 1b 12/16 (75) 11/17 (65) 12/18 (67) 14/16 (88) 49/67 (73)
Hb, hemoglobin; SVR12, sustained virological response (undetectable HCV RNA) at 12 weeks post-treatment; TID16W/TID28W/TID40W, faldaprevir 120
mg once daily and deleobuvir 600 mg three times daily plus ribavirin for 16, 28, and 40 weeks, respectively; BID28W, faldaprevir 120 mg once daily and
deleobuvir 600 mg twice daily plus ribavirin for 28 weeks.
doi:10.1371/journal.pone.0144004.t002
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week 12. Factors found to be significantly associated with hemoglobin<10 g/dL or decreased
by3.5 g/dL in a univariate analysis were age, weight, baseline hemoglobin, rs6051702 geno-
type, and plasma ribavirin concentration (Table 5). With the exception of weight, these factors
remained significant in a multivariate analysis. Plasma levels of faldaprevir and deleobuvir
were not associated with anemia.
Since virological response has been reported to be associated with ribavirin dosing or ane-
mia, we also explored the association between SVR12 and baseline and on-treatment factors
using the data set of patients who completed therapy (excluding those who discontinued for
reasons unrelated to efficacy). Covariates included initial ribavirin dose, ribavirin median
trough plasma concentration through week 12 (measured at every scheduled visit), baseline
hemoglobin, incident anemia (hemoglobin<10 g/dL or change of3.5 g/dL), treatment
group, and rs1127354 and rs6051702 genotypes, in addition to factors known to be associated
with SVR12 (IL28B genotype, genotype 1 subtype, baseline HCV RNA, baseline gamma gluta-
myl transferase (GGT), fibrosis stage, presence of cirrhosis, gender, and age). In a univariate
analysis using pooled data from the ribavirin-containing arms, we found that ribavirin
Table 3. Inosine triphosphatase (ITPA) gene single-nucleotide polymorphisms by treatment arm.
TID16W TID28W TID40W BID28W TID28W-NR
Patients with ITPA data, N 80 80 77 77 46
rs1127354, n (%)
ITPA-deﬁcient (AA/AC) 10 (13) 9 (11) 11 (14) 15 (19) 4 (9)
ITPA-non-deﬁcient (CC) 70 (88) 71 (89) 66 (86) 62 (81) 42 (91)
rs6051702, n (%)
ITPA-deﬁcient (CC/CA) 28 (35) 34 (43) 25 (32) 25 (32) 11 (24)
ITPA-non-deﬁcient (AA) 52 (65) 46 (58) 52 (68) 52 (68) 35 (76)
ITPA-non-deﬁcient genotype at both positions, n (%)
No 31 (39) 35 (44) 28 (36) 31 (40) 11 (24)
Yes 49 (61) 45 (56) 49 (64) 46 (60) 35 (76)
TID16W/TID28W/TID40W, faldaprevir 120 mg once daily and deleobuvir 600 mg three times daily plus ribavirin for 16, 28, and 40 weeks, respectively;
BID28W, faldaprevir 120 mg once daily and deleobuvir 600 mg twice daily plus ribavirin for 28 weeks; TID28W-NR, faldaprevir 120 mg once daily and
deleobuvir 600 mg three times daily, without ribavirin, for 28 weeks.
doi:10.1371/journal.pone.0144004.t003
Fig 3. Mean hemoglobin levels by inosine triphosphatase (ITPA) gene single-nucleotide
polymorphisms, pooled ribavirin-containing arms.
doi:10.1371/journal.pone.0144004.g003
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concentrations through week 12, baseline hemoglobin, and baseline ribavirin dose were signifi-
cantly associated with SVR12, as were the more established predictors including age, genotype
1 subtype, IL28B genotype, GGT, gender, and baseline viral load (Table 6). Neither rs1127354
nor rs6051702 genotype was found to be associated with SVR12. In a multivariate analysis,
ribavirin concentrations, baseline hemoglobin, genotype 1 subtype, and IL28B genotype
remained significantly associated with SVR12 (Table 6).
Ribavirin dose reductions for anemia (as defined by the investigator, not specified by labora-
tory parameters) were more frequent among patients with the ITPA-non-deficient rs1127354
CC genotype than among those with the AA or AC genotype (6.3% vs 2.2%; Table 4), and were
similarly more frequent among those with the ITPA-non-deficient rs6051702 AA genotype
than among those with the CC or CA genotype (8.4% vs 0.9%). Across all ribavirin-containing
treatment groups, SVR12 rates were lower among patients who had ribavirin dose reductions
or interruptions than among those who did not (TID16W, 40% (2/5) vs 61% (46/76);
Table 4. Effect of ITPA SNPs on hemoglobin level, ribavirin dose, and erythropoietin use, pooled ribavirin-containing arms.
ITPA SNP and
genotype, n (%)
rs1127354 ITPA-
deﬁcient AA or AC
(n = 45)
rs1127354 ITPA-
non-deﬁcient CC
(n = 269)
rs6051702 ITPA-
deﬁcient CC or CA
(n = 112)
rs6051702 ITPA-
non-deﬁcient AA
(n = 202)
ITPA-non-deﬁcient
genotype at both
positions (n = 189)
Hb <10 g/dL or decrease
from baseline 3.5 g/dL
1 (2.2) 102 (37.9) 24 (21.4) 79 (39.1) 79 (41.8)
Ribavirin dose reduction
for anemiaa
1 (2.2) 17 (6.3) 1 (0.9) 17 (8.4) 16 (8.5)
Erythropoietin use 0 13 (4.8) 2 (1.8) 11 (5.4) 11 (5.8)
aAnemia as an adverse event deﬁned by investigators (not a laboratory event).
ITPA, inosine triphosphatase gene; SNP, single nucleotide polymorphism; Hb, hemoglobin.
doi:10.1371/journal.pone.0144004.t004
Table 5. Factors associated with anemia in univariate andmultivariate analyses, all treated patients.
Factor Odds Ratio 95% CI p-value
Univariate analysis
Log2 (median trough ribavirin through week 12) 5.35 2.86, 9.98 <0.0001
Baseline hemoglobin, g/dL, <15 vs 15 0.38 0.23, 0.64 0.0002
Age, years, <60 vs 60 0.33 0.16, 0.65 0.0014
Weight, <75 kg vs 75 kg 0.61 0.37, 1.00 0.0495
rs6051702, ITPA-deﬁcient (CC/CA) vs–non-deﬁcient (AA) 0.56 0.32, 0.99 0.0451
Multivariate analysis
Log2 (median trough ribavirin through week 12) 10.62 4.70, 23.99 <0.0001
Baseline hemoglobin, g/dL, <15 vs 15 0.14 0.07, 0.28 <0.0001
Age, years, <60 vs 60 0.32 0.13, 0.80 0.0147
rs6051702, ITPA-deﬁcient (CC/CA) vs–non-deﬁcient (AA) 0.44 0.22, 0.86 0.0163
Ribavirin-containing arms are pooled and all patients have the rs1127354 CC genotype. Covariates
included age (<60 years vs 60 years), gender, weight (<75 kg vs 75 kg), ﬁbrosis stage (F0–F2 vs F3–
F4), presence of cirrhosis (yes/no), body mass index (<25 kg/m2 vs 25 kg/m2), rs6051702 genotype
(ITPA-deﬁcient (CC/CA) vs–non-deﬁcient (AA)), baseline hemoglobin (<15 g/dL vs 15 g/dL), faldaprevir,
deleobuvir, and ribavirin trough levels through week 12, and baseline ribavirin dose. ITPA, inosine
triphosphatase.
doi:10.1371/journal.pone.0144004.t005
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TID28W, 25% (3/12) vs 65% (44/68); TID40W, 42% (5/12) vs 54% (35/65); and BID28W, 40%
(4/10) vs 74% (50/68)).
Discussion
The results of this study suggest that ITPA SNPs may help predict anemia in chronic hepatitis
C patients treated with interferon-free regimens that contain ribavirin. We found that the
ITPA-non-deficient genotypes rs1127354 CC and rs6051702 AA were associated with the
development of anemia during treatment with faldaprevir, deleobuvir, and ribavirin in the
SOUND-C2 study. Ribavirin is an important component of several interferon-free regimens
[5, 8], and studies have shown the benefit of including ribavirin with direct-acting antivirals,
for example, in patients treated with the combination of paritaprevir/ritonavir/ombitasvir and
dasabuvir who are infected with HCV genotype 1a, HCV genotype 1b in the presence of cirrho-
sis, or HCV genotype 4 [5, 17, 18, 19]. Most interferon-free regimens recommended for
patients with cirrhosis contain ribavirin [9]. Although the development of faldaprevir and
Table 6. Covariates evaluated for association with SVR12 in univariate andmultivariate analyses.
Factor Odds Ratio 95% CI p-value
Univariate analysis
Log2 (median trough ribavirin through week 12) 7.37 3.71, 14.64 <0.0001
Baseline hemoglobin, g/dL, <15 vs 15 3.75 2.15, 6.56 <0.0001
Age, years, <60 vs 60 0.11 0.03, 0.49 0.0034
Baseline ribavirin dose per day and kg 1.16 1.01, 1.33 0.0305
Genotype 1 subtype, 1b vs 1a 6.04 3.43, 10.63 <0.0001
IL28B genotype, CC vs non-CC 2.85 1.41, 5.78 0.0036
Baseline GGT, elevated vs normal 0.41 0.25, 0.70 0.0010
Gender, male vs female 0.33 0.19, 0.58 <0.0001
Baseline HCV RNA, 800,000 IU/mL vs <800,000 IU/mL 0.39 0.16, 0.98 0.0457
rs1127354, ITPA-deﬁcient (AA/AC) vs–non-deﬁcient (CC) 1.00 0.49, 2.03 0.9915
rs6051702, ITPA-deﬁcient (CC/CA) vs–non-deﬁcient (AA) 1.31 0.76, 2.26 0.3303
Hb <10 g/dL or change from baseline 3.5 g/dL, yes vs no 1.25 0.72, 2.16 0.43222
Fibrosis stage, F0–F2 vs F3–F4 0.76 0.40, 1.41 0.3823
Cirrhosis, yes vs no 0.95 0.39, 2.30 0.9110
Randomized treatment group
TID16W vs BID28W 0.75 0.37, 1.50 0.4123
TID28W vs BID28W 0.87 0.42, 1.79 0.7056
TID40W vs BID28W 0.86 0.41, 1.83 0.7032
Multivariate analysis
Log2 (median trough ribavirin through week 12) 7.86 3.31, 18.67 <0.0001
Baseline hemoglobin, g/dL, <15 vs 15 3.35 1.71, 6.59 0.0004
Genotype 1 subtype, 1b vs 1a 6.01 3.06, 11.79 <0.0001
IL28B genotype, CC vs non-CC 7.05 2.90, 17.12 <0.0001
Based on patients who completed therapy (excluding those who discontinued for reasons unrelated to
efﬁcacy). Ribavirin-containing arms are pooled. ITPA, inosine triphosphatase; GGT, gamma glutamyl
transferase; Hb, hemoglobin; TID16W, faldaprevir 120 mg once daily, deleobuvir 600 mg three times daily,
and ribavirin for 16 weeks; BID28W, faldaprevir 120 mg once daily, deleobuvir 600 mg twice daily, and
ribavirin for 28 weeks; TID40W, faldaprevir 120 mg once daily, deleobuvir 600 mg three times daily, and
ribavirin for 40 weeks.
doi:10.1371/journal.pone.0144004.t006
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deleobuvir has been halted, our findings remain relevant since they may apply to treatment
with other interferon-free, ribavirin-containing regimens.
In the SOUND-C2 study, 10% (32/316) of patients in the pooled ribavirin-containing arms
had a hemoglobin level<10 g/dL. This incidence of hemoglobin<10 g/dL is considerably
lower than that observed during studies of peginterferon-containing regimens. In the START-
Verso1 study, 26% of patients receiving faldaprevir with peginterferon and ribavirin had a
hemoglobin level<10 g/dL, as did 30% of patients receiving peginterferon and ribavirin in the
IDEAL study, and 50% of those receiving boceprevir plus peginterferon and ribavirin in the
SPRINT-2 study [1, 20, 21]. The higher rates of anemia in these studies suggest that the myelo-
suppressive action of peginterferon may contribute to hemoglobin reduction during chronic
HCV therapy, although caution should be exercised when comparing data across studies.
A small increase in the SVR12 rate was observed among patients who developed hemoglo-
bin<10 g/dL or a decrease from baseline of3.5 g/dL, compared with patients who did not
have such hemoglobin reductions (65% vs 57%). This observed difference in SVR12 may be
due in part to differential rates of early discontinuation, since patients who discontinue early
are both less likely to experience anemia and less likely to achieve SVR12 than those who con-
tinue treatment. Higher SVR rates among patients with incident anemia have been observed
during treatment with peginterferon-containing regimens [1, 20]. However, it has been sug-
gested that anemia is only a marker for ribavirin exposure and that higher SVR rates in anemic
patients may be due to higher plasma ribavirin levels [20, 22, 23].
Our analysis of ITPA SNPs showed that patients with the ITPA-non-deficient rs112354CC
genotype had greater hemoglobin reductions over time than patients with the ITPA-deficient
AA or AC genotype. Of 103 patients with hemoglobin<10 g/dL or a decrease of3.5 g/dL, all
but one had the ITPA-non-deficient rs112735CC genotype. Our finding of a strong association
between ITPA genotypes and the development of anemia is consistent with the results of earlier
studies. Fellay and co-workers found that among patients receiving peginterferon and ribavirin,
SNPs at positions rs6051702 and rs1127354 were independently associated with the develop-
ment of anemia [11], while others have shown that ITPA genotypes are associated with anemia
during triple therapy including protease inhibitors [24, 25]. Consistent with those earlier stud-
ies in patients receiving peginterferon-containing regimens, our results show that the ITPA
rs1127354 CC genotype is a predictor of ribavirin-induced anemia during interferon-free
therapy.
Among patients with the rs1127354 CC genotype, we found that other independent predic-
tors of anemia were age60 years, baseline hemoglobin15 g/dL, the rs6051702 AA geno-
type, and plasma ribavirin levels. Others have found that low baseline hemoglobin is a
predictor of anemia during treatment with telaprevir-based triple therapy [25]. Our finding
that a high baseline hemoglobin is associated with anemia is likely due to the definition of ane-
mia in this analysis—hemoglobin<10 g/dL or decreased from baseline by3.5 g/dL; patients
with high baseline hemoglobin appear to be more likely than those with lower levels to experi-
ence a decrease of3.5 g/dL. The predictors of anemia that we identified in the context of
interferon-free treatment can help clinicians identify patients who may need to be monitored
more closely during ribavirin-containing, interferon-free therapy, including patients with
advanced age, low baseline hemoglobin, or with the ITPA-non-deficient genotypes at both the
rs1127354 and the rs6051702 positions. Early dose reduction of ribavirin or use of erythropoie-
tin may help manage anemia in susceptible patients.
Since treatment response has been reported to be associated with ribavirin dose and/or
anemia, we also explored predictors of SVR12, taking into account ITPA genotypes at both
the rs1127354 and the rs6051702 positions, baseline hemoglobin levels, and on-treatment
ribavirin concentrations. Multivariate analysis showed that ribavirin concentration, baseline
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hemoglobin, genotype 1 subtype, and IL28B genotype were independent predictors of SVR12.
Neither ITPA SNP was associated with SVR12. This may seem surprising since we found a
strong association between both ITPA-non-deficient genotypes and anemia. However, as
some researchers have suggested, anemia may not be directly related to SVR: Holmes and co-
workers recently showed in a large cohort of peginterferon- and ribavirin-treated patients that
the relationship between anemia and SVR is not mechanistic, and is most likely explained by
plasma ribavirin levels [23]. Our results support this theory: in our study, plasma ribavirin
concentrations were independently associated with SVR12 (based on the multivariate analy-
sis) while the impact of ribavirin-induced anemia on SVR12 was minimal. This may reflect
the fact that effective levels of ribavirin were also achieved in patients without anemia, who
were most likely protected by ITPA-deficient genotypes. The inclusion of plasma ribavirin lev-
els in the multivariate analysis enabled us to show that ribavirin exposure, and not anemia, is
a predictor of SVR12.
Our understanding of the role of host genetics in HCV treatment response and tolerability
is evolving, and will help clinicians tailor treatments to maximize response and minimize
adverse events. Host IL28B genotype is known to be a strong predictor of response to inter-
feron-based therapy [26, 27], while patients with variants in the ITPA gene are known to be
protected against ribavirin-induced anemia during treatment with peginterferon-containing
regimens [12]. The standard of care for chronic hepatitis C now includes interferon-free regi-
mens, some including ribavirin and others ribavirin-free [5, 8, 28]. Our results suggest that
ITPA genotypes can predict anemia during treatment with interferon-free, ribavirin-contain-
ing regimens. We also showed that in patients receiving such a regimen, SVR is not associated
with anemia, and is associated with plasma ribavirin levels. One implication of our study is that
patients known to have a genotype that does not protect against anemia may require more
monitoring during treatment with ribavirin-containing, interferon-free regimens. Future iden-
tification of additional SNPs associated with anemia or with other adverse effects will help
optimize therapy by identifying the best treatment regimens and management strategies for
individual patients.
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